WAVEMAN · COMPANY

XOMA · Xoma Royalty Corp

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

XOMA

Name: XOMA Royalty Corp (XOMA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

XOMA Royalty Corp

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000791908

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+55.6%

XBRL, annual

NET MARGIN

306.4%

CONVERSIONS · 180D

codes C/M, not in net · $20.2M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

57 funds added or opened last quarter

below 53% of Pharma & Biotech

REVENUE

+55.6% year over year

more than 80% of Pharma & Biotech

MARGIN

306.4% net margin

more than 98% of Pharma & Biotech

BUYBACKS

$264.0K repurchased, FY to 2026-03-31

below 93% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

57 funds added or opened positions in the latest 13F quarter, of 99 holders.

Ligand Pharmaceuticals Incorporated disclosed a 5%+ stake (47.0%) in the last six months.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows 57 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for XOMA Royalty Corp in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Hughes Owen

Chief Executive Officer

BUY

2025-12-04

100,000.0

$2.5M

BURNS THOMAS M.

SVP, Finance & CFO

SELL

2025-09-22

15.0

$552

BURNS THOMAS M.

SVP, Finance & CFO

SELL

2025-09-22

4,300.0

$154.7K

BURNS THOMAS M.

SVP, Finance & CFO

SELL

2025-09-22

15.0

$554

Sitko Bradley

Chief Investment Officer

BUY

2025-06-30

2,000.0

$50.8K

73 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 68 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BVF INC/IL

7,593,303.0 sh

$322.7M

MORGAN STANLEY

1,697,167.0 sh

$72.1M

FMR LLC

1,605,532.0 sh

$68.2M

Woodline Partners LP

1,114,363.0 sh

$47.4M

Newtyn Management, LLC

709,247.0 sh

$30.1M

5%+ owners

13D = intent to influence · 13G = passive

Ligand Pharmaceuticals Incorporated

ACTIVIST 13D · 2026-05-01

47.0%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Inception Portfolio

$5.5M POSITION · AS OF 2026-03-31

2.3%

EQ/Morgan Stanley Small Cap Growth Portfolio

$3.6M POSITION · AS OF 2026-03-31

0.9%

Morgan Stanley Insight Fund

$7.9M POSITION · AS OF 2026-03-31

0.7%

Global Insight Portfolio

$356.0K POSITION · AS OF 2026-03-31

0.7%

Ultra-Small Company Market Fund

$513.8K POSITION · AS OF 2026-03-31

0.4%

Invesco NASDAQ Future Gen 200 ETF

$52.7K POSITION · AS OF 2026-02-28

0.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Mr. Hughes

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$1.1M

$1.3M

$789.2K

+45%

—

2024

$5.8M

$6.4M

$731.5K

+43%

—

2023

$2.5M

$2.1M

$5.4M

+1%

—

2022

$2.3M

$1.0M

-12%

—

2021

$3.5M

$1.1M

-53%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$10.3M	$6.7M	$2.6M	$4.2M
OPERATING INCOME	$11.4M	$-40.0M	$-41.8M	$-17.4M
NET INCOME	$31.7M	$-13.8M	$-40.8M	$-17.1M
EPS (DILUTED)	1.46	-1.65	-4.04	-1.98
OPERATING CASH FLOW	$2.9M	$-13.7M	$-18.2M	$-12.9M
CASH	$82.9M	$101.7M	$153.3M	$57.8M
LONG-TERM DEBT	$96.5M	$106.9M	$118.5M	$0
BUYBACKS	$16.0M	$13.0K	—	—
DIVIDENDS PAID	$5.5M	$5.5M	$5.5M	$5.5M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE